Skip to main content

(Moncton, NB) – May 18, 2018 – Picomole Inc. has announced the appointment of Dr. Stephen Douglas Graham as CEO. He will assume responsibilities on May 28th, 2018.

For the past three years Dr. Steve Graham has worked with Picomole as the Special Advisor responsible for Research and Business Development.  During this period Picomole has successfully restarted its operations and developed its research program to the point where it’s on the cusp of proving its technology in a clinical trial.  He has also worked with the Board of Directors to oversee two successful capital investment rounds.

Dr. Stephen Graham

“We now have sufficient capital to finish the clinical research and build the next generation of analyzer and samplers” said Dr. Graham. “I am thankful to the Board of Directors for this unique opportunity to lead Picomole’s development into a world leader in breath analysis applied to human health.

“We are extremely pleased to have Steve driving Picomole’s vision and business plan.  Not only does he already know the business inside out, he also brings a wealth of experience, knowledge and contacts to our team” says Picomole Chairman, Louis Babineau.

Dr. Graham is a Pharmacist and Epidemiologist by training.  For the past eight years he worked in the Medical Divisions of two multinational pharma companies.  Here he successfully developed networks of clinical experts and facilitated research projects aimed at optimizing Primary Care delivery.


Breathe BioMedical Headquarters
191 Halifax Street
Moncton, NB E1C 9R6

T: 506-855-2400

Breathe BioMedical Inc.
245 Main, 2nd Floor
Cambridge, MA 02142

T: 617-203-2089